Dorobek publikacyjny NIO-PIB w Warszawie od 2021 r*.
2025
- Ahn M., Lisberg A., Goto Y., Sands J., Hong M., Paz-Ares L., Pons-Tostivint E., Pérol M., Felip E., Sugawara S., Hayashi H., Cho B., Blumenschein G., Shum E., Lee J., Heist R., Cornelissen R., Chang W., Kowalski D., Zebger-Gong H., Chargualaf M., Gu W., Lan L., Howarth P., Joseph R., Okamoto I.: A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC, Journal of Thoracic Oncology, 2025. DOI:10.1016/j.jtho.2025.06.002 [w druku]
- Albshesh A., Kucha P., Pugliese D., Amiot A., Mahajna H., Eder P., Savarino E.V., Vavricka S., Castiglione F., Imperatore N., Krznaric Z., Abitbol C.M., Hen O., Zaborowska M., Carbonnel F., Cuccia G., Lorenzon G., Zittan E., Zagórowicz E., Maniero D., Ben-Horin S., Kopylov U.: Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study. Digestive and Liver Disease. 2025 Oct 27:S1590-8658(25)01146-6. DOI:10.1016/j.dld.2025.09.032 [w druku]
- Amaral T., Nanz L., Higuita L., Ascierto P., Berking C., Couselo E., Donia M., Dummer R., Gutzmer R., Haushild A., Jalving M., Lee R., Lorigan P., Marquez-Rodas I., Michelin O., Nathan P., Robert C., Schadendorf D., Sobczuk P., Flatz L., Leiter U., Garbe C.: A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research, European Journal of Cancer, vol. 215, 2025, nr art.115160. DOI:10.1016/j.ejca.2024.115160
- Amat-Fernandez C., Garin O., Luer-Aguila R., Pardo Y., Briseño R., Lizano-Barrantes C., Rojas-Concha L., Thong M.S.Y., Apolone G., Brunelli C., Caraceni A., Couespel N., Bos N., Groenvold M., Kaasa S., Ciliberto G., Lombardo C., Pietrobon R., Pravettoni G., Sirven A., Vachon H., Gilbert A., Velikova G., Ferrer M., EUonQoL Working Group.: Systematic review of the needs and health-related quality of life domains relevant to people surviving cancer in Europe. Quality of Life Research, 2025, vol. 34, nr 4, s. 913-936 [w ramach grupy badawczej: Ługowska I.]. DOI:10.1007/s11136-024-03884-w
- Babiker H., Picozzi V., Chandana S., Melichar B., Kasi A., Gang J., Gallego J., Bullock A., Chunyi H., Wyrwicz L., Hitre E., Osipov A., De La Fouchardiere C., Ales I., Dragovich T., Lee W., Feeney K., Philip P., Ueno M., Van Cutsem E., Seufferlein T., Macarulla T., PANOVA-3 Study Investigators: Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study, Journal of Clinical Oncology, 2025, vol. 43, nr 21, s. 2350-2360. DOI:10.1200/JCO-25-00746
- Bakuła-Zalewska E., Domanski H., Klijanienko J.: Fine-needle aspiration of parotid gland sialoblastoma. Two new cases and literature review, Diagnostic Cytopathology, 2025, vol. 53, nr 8, s. E155-E159. DOI:10.1002/dc.25480
- Baluszek S., Kober P., Myśliwy I., Oziębło A., Mandat T., Jeżewski M., Bujko M.: Determining the Biological Features of Aggressive Meningioma Growth with Transcriptomic Profiling, Cancers, 2025, vol. 17, nr 20, nr art. 3324,. DOI:10.3390/cancers17203324
- Bałata A., Szombara E., Nowecki Z., Pogoda K.: The use of granulocyte colony-stimulating factors in the management of breast cancer patients, Frontiers in Oncology, 2025, vol. 15, nr art. 1613199. DOI:10.3389/fonc.2025.1613199
- Barańska K., Niemas K., Pełka K., Kunikowska J.: PET/CT in the Imaging of CNS Tumors, Seminars in Nuclear Medicine, 2025, vol. 55, nr 4, s. 475-486. DOI:10.1053/j.semnuclmed.2025.04.002
- Barańska K., Niemas K., Wojewódzka-Mirocha M., Kabat J., Dedecjus M.: Spectacular effect of [177Lu]Lu-PSMA-617 therapy in a patient with hormone-resistant prostate cancer after failure of other therapeutic options, Nuclear Medicine Review, 2025, vol. 28, s. 61--64. DOI:10.5603/nmr.108217
- Berning P., Ngoya M., Kim W., Shumilov E., Wu D., Huang H., Cairoli A., Tucci A., Dachy G., Gounot R., Wilke A., Scheid C., Dreger P., Lopez Lorenzo J., Bloor A., Romejko-Jarosińska J., Gadisseur A., Schroers R., Reményi P., Gabellier L., Poiani M., Halahleh K., Galimard J., Lenz G., Sureda A., Bazarbachi A., Glass B., Schmitz N.: Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working Party, HemaSphere, 2025, vol. 9, nr 8, nr art. e70184. DOI:10.1002/hem3.70184
- Bębenek W., Gajek A., Marczak A., Malý J., Smejkal J., Statkiewicz M., Rusetska N., Bryś M., Rogalska A.: MK-8776 and olaparib combination acts synergistically in hepatocellular carcinoma cells, demonstrating lack of adverse effects on liver tissues in ovarian cancer PDX model, International Journal of Molecular Sciences, vol. 26, nr 2, 2025, nr art.834. DOI:10.3390/ijms26020834
- Bidard F., Mayer E., Park Y., Janni W., Ma C., Cristofanilli M., Bianchini G., Kalinsky K., Iwata H., Chia S., Fasching P., Brufsky A., Nowecki Z., Pascual J., Moreau L., Chen S., Karadurmus N., Gal-Yam E., Jung K., Pernas S., Mcclain S., He W., Klinowska T., Huang-Bartlett C., Turner N., SERENA-6 Study Group: First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer, New England Journal of Medicine, 2025, vol. 393, nr 6, s. 569–580. DOI:10.1056/NEJMoa2502929
- Biegała Ł., Statkiewicz M., Gajek A., Szymczak-Pajor I., Rusetska N., Śliwińska A., Marczak A., Mikula M., Rogalska A.: Molecular mechanisms restoring olaparib efficacy through ATR/CHK1 pathway inhibition in olaparib-resistant BRCA1/2MUT ovarian cancer models, Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1871, nr 2, 2025, nr art.167574. DOI:10.1016/j.bbadis.2024.167574
- Bizzarri N., Guidi G., Pavone M., Pedone Anchora L., Rychlik A., Goglia M., Fanfani F., Scambia G., Querleu D.: Laparoscopic para-uterine lymphovascular tissue sentinel lymph node biopsy with indocyanine green in cervical cancer, International Journal of Gynecological Cancer, 2025, nr art. 101744. DOI:10.1016/j.ijgc.2025.101744 [w druku]
- Bjelic-Radisic V., Cardoso F., Weis J., Pogoda K., Arraras J., Greimel E., Bottomley A., Cameron D., Brain E., Hartup S., Da Costa Vieira R., Hoefnagels N., Huang C., Shamieh O., Pinto M., Belay Y., Serpentini S., Bleiker E., Nookala M., Shimomura A., Sturm-Inwald E., Getu M., Bliem B., Astrup G., Morag O., Kikawa Y., Kuljanic K., Nevries N., Sprangers M., Aaronson N., Sinai P., Tomaszweski K., Galalae R., Conroy T., Duhoux F., Chie W., Velikova G.: An international Phase IV field study - psychometric properties of the updated module on assessing quality of life of patients with breast cancer EORTC QLQ-BR42, Breast, vol. 80, 2025, nr art.103890. DOI:10.1016/j.breast.2025.103890
- Blondeaux E., Delucchi V., Mariamidze E., Bernstein-Molho R., Frank S., Ferrari A., Linn S., Jeong Kim H., Agostinetto E., Paluch-Shimon S., Cortesi L., Di Meglio A., Balmana J., Yerushalmi R., Rodriguez-Wallberg K., Renaud T., Cui W., Moore H., Wong S., Pogoda K., Lustberg M., Phillips K., Han S., Puglisi F., Vernieri C., Bajpai J., Sonnenblick A., Rousset-Jablonski C., De Marchis L., De Giorgi U., Bianchini G., Texeira L., Duhoux F., Villarreal-Garza C., Sini V., Fruscio R., Del Mastro L., Demeestere I., Azim H., Peccatori F., Partridge A., Lambertini M.: Breastfeeding after breast cancer in young BRCA carriers, JNCI-Journal of the National Cancer Institute, 2025, nr art. djaf177. DOI:10.1093/jnci/djaf177 [w druku]
- Blondeaux E., Sonnenblick A., Agostinetto E., Bas R., Kim H., Franzoi M., Bernstein-Molho R., Linn S., Kwong A., Pogoda K., Balmana J., Smeets A., Bajpai J., Moore H., Partridge A., Phillips K., Toss A., Rousset-Jablonski C., Peccatori F., Renaud T., Ferrari A., Paluch-Shimon S., Mando P., Lee J., Fruscio R., Cui W., Wong S., Vernieri C., Ruddy K., Dieci M., Matikas A., Rozenblit M., Guven D., Lee M., Villarreal-Garza C., Hwang S., De Marchis L., Puglisi F., Kemp Z., Meireles P., Parokonnaya A., Werutsky G., Okano M., Azim H., Mati K., Rosenberg S., Gelber R., Boni L., Lambertini M.: Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study, Lancet Oncology, 2025,. DOI:10.1016/S1470-2045(25)00152-4
- Bobak K., Bartnik E., Czarnecka A.: Mechanizmy oporności na leczenie ukierunkowane molekularnie i immunoterapię u chorych na czerniaki. W: Nowe terapie systemowe u chorych na nowotwory skóry. Wydanie II / Rutkowski Piotr (red.), 2025, Via Medica, ISBN 978-83-68588-43-9, s. 82-104
- Bobak K., Synoradzki K., Sulejczak D., Rutkowski P., Czarnecka A.: Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma. W: Cancer Immunoediting / Rezaei Nima (red.), 2025, Springer, ISBN 978-3-032-00765-0, s. 539-557 DOI:10.1007/978-3-032-00765-0_179
Podsumowanie:
Liczba publikacji: 2478
Łączna suma IF: 17377,927
Łączna liczba pkt. min.: 195595
* Informacje o publikacjach z lat 2020 i wcześniejszych zawiera baza
Omega PSIR. Uwaga! Punktacja w systemie Omega PSIR tylko częściowo jest poprawna.